




UNIVERSITI PUTRA MALAYSIA

**ORAL IMMUNIZATION WITH CHOLERA DNA VACCINE EMPLOYING
MICROENCAPSULATION DELIVERY SYSTEM**

NADINE HAYUDINI NOGRALES

FPSK(p) 2013 2

**ORAL IMMUNIZATION WITH CHOLERA DNA VACCINE EMPLOYING
MICROENCAPSULATION DELIVERY SYSTEM**



By

NADINE HAYUDINI NOGRALES

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia
in Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

January 2013

To
~My Beloved Family~



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

ORAL IMMUNIZATION WITH CHOLERA DNA VACCINE EMPLOYING MICROENCAPSULATION DELIVERY SYSTEM

By

NADINE HAYUDINI NOGRALES

January 2013

Chairman: Professor Rozita Rosli, PhD

Faculty: Medicine and Health Sciences

Cholera disease remains to be a major public health problem in areas with poor sanitation, unsafe water supplies or in cases of epidemic outbreaks. Current oral whole-cell cholera vaccines are unable to elicit long-term protection against cholera and require maintenance of cold-chain during transport. Another vaccination strategy includes delivery of genetic components of the infectious agent. Plasmids carrying gene-coding sequences for immunostimulatory antigens such as the cholera toxin B subunit (*ctxB*) and/or the toxin coregulated pilin A (*tcpA*) genes were explored in this study as DNA vaccines for cholera. Advantages of DNA vaccines include relatively low cost and chemical stability during storage.

A non-viral delivery system described as microencapsulation into alginate material, a natural polysaccharide, was utilized in this study as an oral DNA delivery vehicle. The efficiency of DNA encapsulation was evaluated *in vitro* through characterization of the physical and behavioral properties of the microspheres. Subsequently, comparative evaluation of the *in vivo* immunoglobulin production after vaccination with encapsulated DNA vaccine was performed.

Alginate microspheres were produced through water-in-oil (w/o) emulsification. The average size of alginate microspheres was about $46.88 \pm 3.07 \mu\text{m}$ in diameter whereby significant size reduction ($p=0.028$) was attributed through utilization of 1.0% Span80 in the preparation. Plasmid DNA (pDNA) was encapsulated within microspheres with encapsulation efficiencies ranging from 72.9 to 74.4% and a maximum pDNA load of $6 \mu\text{g}$ for each preparation. In simulated gastrointestinal conditions, alginate microspheres demonstrated shrinkage and minimal release of pDNA in pH 1.2 while exhibiting swelling properties in pH 9.0 with consequent pDNA release about twice the pDNA amount released in acidic environment ($p<0.01$).

As proof-of-concept studies *in vivo*, orally administered pDNA-loaded alginate microspheres comprising the mammalian expression vector (pVAX), designed for DNA vaccine development, carrying the GFP reporter gene was performed. pVAX-GFP loaded-alginate microspheres, at doses of $50 \mu\text{g}$, $100 \mu\text{g}$ and $150 \mu\text{g}$ pDNA, were delivered through oral feeding needle to BALB/c mice. Tissue biodistribution, investigated through flow cytometric analysis, demonstrated GFP positive intestinal cells ($<1.0\%$) for the $100 \mu\text{g}$ dose, a 1.3-fold higher expression as compared to $50 \mu\text{g}$ dose. Succeeding experiments were conducted with DNA vaccines using the same approach.

Oral delivery of DNA vaccine loaded-microspheres were performed on BALB/c mice and New Zealand White (NZW) rabbits. Test animals and control groups were immunized with pVAX-*ctxB* and/or pVAX-*tcpA* encapsulated within alginate microspheres. The production of antibodies observed among the test animals were

compared with the control groups. Stool sIgA levels or the mucosal sIgA among vaccinated mice groups (100 µg dose) showed an increase as compared to controls with an average 6.3-fold, 1.6-fold and 1.9-fold increase at day 7, 14 and 21, respectively. The response in the rabbits were lower (on average only 29% or 159% higher than controls), observed at day 21. These results demonstrate local immune responses at mucosal surfaces of the intestinal tract among vaccinated mice and rabbits.

Therefore, the alginate microspheres used in this study have shown to be potential carriers for cholera DNA vaccine into the intestinal mucosa surfaces; although further improvements are needed. The overall strategy of alginate microencapsulation which served as oral DNA vaccine therapy in this study may also serve as a delivery system for other forms of antigens or biological substances through the oral route.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**PELALIAN ORAL DENGAN VAKSIN DNA TAUN MENGGUNAKAN
SISTEM PENYAMPAIAN PEMIKROKAPSULAN**

Oleh

NADINE HAYUDINI NOGRALES

Januari 2013

Pengerusi: Profesor Rozita Rosli, PhD

Fakulti: Perubatan dan Sains Kesihatan

Taun masih kekal sebagai masalah kesihatan awam yang besar di kawasan yang kurang bersih atau tidak dilengkapi bekalan air bersih atau dalam kes wabak jangkitan. Vaksin taun seluruh sel oral semasa tidak dapat mengaktifkan perlindungan jangka masa panjang terhadap taun serta memerlukan penyenggaraan simpanan sejuk berangkai sepanjang pengangkutan. Strategi pemvaksinan lain merangkumi penyampaian komponen genetik agen berjangkit. Plasmid yang membawa jujukan pengekod gen bagi antigen perangsang imun seperti gen-gen subunit B toksin taun (*ctxB*) dan/atau pilin A diregulasi bersama toksin (*tcpA*) dikaji dalam penyelidikan ini sebagai vaksin DNA bagi penyakit taun. Antara kelebihan vaksin DNA termasuklah kos yang kurang serta kestabilan kimia semasa penyimpanan.

Salah satu sistem bukan berantarkan virus yang dihuraikan sebagai pemikrokapsulan ke dalam bahan alginat, sejenis polisakarida semula jadi, digunakan sebagai penyampai oral DNA dalam kajian ini. Keberkesanan pengkapsulan DNA dinilai secara *in vitro* menerusi pencirian sifat fizikal dan

perlakuan mikrosfera. Berikutan itu, penilaian secara perbandingan penghasilan *in vivo* imunoglobulin setelah pemvaksinan menggunakan vaksin DNA yang dikapsulkan dijalankan.

Mikrosfera alginat dihasilkan melalui pengemulsian air-dalam-minyak. Saiz purata mikrosfera alginat ialah saiz diameter $46.88 \pm 3.07 \mu\text{m}$, di mana pengurangan signifikan saiz ($p=0.028$) berlaku melalui penambahan 1.0% Span80 semasa penyediaan mikrosfera. DNA plasmid dikapsulkan dalam mikrosfera dengan keberkesanan pengkapsulan berjulat daripada 72.9 sehingga 74.4% serta muatan plasmid maksimum pada 6 μg bagi setiap penyediaan. Dalam simulasi keadaan gastrousus, mikrosfera alginat menunjukkan pengecutan dan pelepasan minimum plasmid pada pH 1.2 serta menunjukkan ciri pengembangan pada pH 9.0 dengan pelepasan plasmid yang berikutan pada kadar dua kali ganda berbanding dengan jumlah yang terlepas dalam keadaan berasid ($p<0.01$).

Sebagai kajian pembuktian konsep *in vivo*, mikrosfera alginat bermuatan plasmid diberikan secara oral terdiri daripada vektor DNA plasmid ekspresi mamalia (pVAX), yang direka bagi penghasilan vaksin DNA dan membawa gen pelapor GFP. Mikrosfera alginat dengan muatan pVAX-GFP disampaikan pada dos 50 μg , 100 μg dan 150 μg , melalui jarum pembekal makanan kepada mencit BALB/c. Taburan bio tisu yang dikaji melalui analisis sitometri aliran, menunjukkan sel usus yang positif GFP (<1.0%) pada tahap 1.3 kali ganda lebih tinggi bagi dos 100 μg berbanding dengan dos 50 μg . Eksperimen yang berikutnya dijalankan dengan vaksin DNA menggunakan pendekatan yang sama.

Penyampaian oral mikrosfera dengan muatan vaksin DNA dilakukan terhadap mencit BALB/c dan arnab *New Zealand White* (NZW). Kumpulan haiwan yang diuji dan kawalan dilalakan dengan pVAX-*ctxB* dan/atau pVAX-*tcpA* yang dikapsulkan di dalam mikrosfera alginat. Aras antibodi yang dihasilkan dalam kalangan haiwan yang diuji ditentukan dan dibandingkan dengan kawalan. Aras sIgA tinja atau sIgA mukosa dalam kalangan mencit (dos 100 µg) menunjukkan peningkatan berbanding dengan kumpulan kawalan dengan purata peningkatan 6.3 kali ganda, 1.6 kali ganda dan 1.9 kali ganda, masing-masing pada hari ke-7, ke-14 dan ke-21. Tindak balas dalam kalangan arnab adalah lebih rendah (secara purata hanya 29% atau 159% lebih tinggi daripada kawalan), diperhatikan pada hari ke-21. Hasil keputusan ini menunjukkan tindak balas lokal di permukaan mukosa saluran usus dalam kalangan mencit dan arnab yang dilalakan.

Oleh itu, mikrosfera alginat yang digunakan dalam kajian ini telah didapati menunjukkan potensi sebagai pembawa vaksin DNA taun ke permukaan mukosa usus; walau bagaimanapun penambahbaikan lebih lanjut diperlukan. Strategi keseluruhan bagi pemikrokapsulan alginat yang bertindak sebagai terapi oral vaksin DNA taun dalam kajian ini mungkin boleh juga digunakan sebagai sistem penyampai antigen atau bahan biologi lain melalui laluan oral.

ACKNOWLEDGEMENTS

First and foremost, all praise and glory to the Almighty Allah. I am eternally grateful for His grace and blessings throughout my life and my studies.

My sincere thanks and gratitude to my supervisor **Prof. Dr. Rozita bt Rosli** whose invaluable expertise, advise, guidance and wisdom have helped me greatly to achieve various goals and accomplishments in the realm of postgraduate studies and scientific research.

I am honored and grateful as well to my supervisory committee. My sincerest gratitude to **Dr. Syahril Bin Abdullah**, he exemplified his undying passion for research. His insights, advises and support throughout the years are very much appreciated. My gratitude to **Prof. Dr. Mariana Nor Bt Shamsudin** for all the help, advise and support. I would also say special thanks to **Assoc. Prof. Dr. Sharmili Vidyadaran** for her generous and kind support during my study.

I have also been privileged to work within the research facility, SingHealth Experimental Medicine Centre in Singapore. To the Director and all the staff of SEMC, thank you for accommodating our research project. Thanks to the Immunology laboratory of UPM as well for the use of facilities.

I am thankful to the laboratory staff who have been competent facilitators as well as like family to me. My appreciation to **Puan Salimah bt Mohd Said, Puan Hazlen Saleh** and **Puan Puspaleela Kaliyappanthey**.

Special thanks to all my colleagues and dearest friends of Medical Genetics Laboratory, especially for the generosity and kindness which have shared a great deal in my postgraduate years. My appreciation to **Wendy Yeo Wai Yeng, Eunice Ngai Siew Ching, Low Poh Tee, Aimi Melati Hanafi, Pushpa Gandhi Sangaran, Marlini Mahadzar, Omar Harastany, Razieh Amini, Zahra Yekta Moghaddam Noudehi** and all postgraduate student members of the laboratory.

And thanks to all those who have helped me but may not find their names in my narration.

Last but not least, I am eternally indebted to my **parents, brother, husband** and **family** for their unconditional love, support and inspiration. Words will never be enough to express my gratitude.

To all, thank you so much.

I certify that an Examination Committee has met on (date) to conduct the final examination of Nadine Hayudini Nograles on his Doctor of Philosophy thesis entitled “Oral Immunization by Cholera DNA Vaccine Employing Microencapsulation Delivery Systems” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Examination Committee were as follows:

Prof. Dr. Elizabeth George, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Prof. Dr. Abdul Rahman bin Omar, PhD

Professor
Institute of Bioscience
Universiti Putra Malaysia
(Internal Examiner)

Prof. Dr. Raha bt Hj Abdul Rahim, PhD

Professor
Faculty of Biotechnology and Biomolecular Sciences
Universiti Putra Malaysia
(Internal Examiner)

Dr. Martin C. Garnett, PhD

School of Pharmacy
University of Nottingham
United Kingdom
(External Examiner)

SEOW HENG FONG, PhD

Professor and Deputy Dean
School of Graduate Students
Universiti Putra Malaysia

Date:

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Rozita bt Rosli, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Mariana Nor bt Shamsudin, PhD

Professor
Institute of Bioscience
Universiti Putra Malaysia
(Member)

Syahrilnizam bin Abdullah, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Students
Universiti Putra Malaysia

Date:

TABLE OF CONTENTS

	Page
DEDICATION	ii
ABSTRACT	iii
ABSTRAK	vi
ACKNOWLEDGEMENTS	ix
APPROVAL	xi
DECLARATION	xiii
LIST OF TABLES	xix
LIST OF FIGURES	xx
LIST OF ABBREVIATIONS	xxiii
CHAPTER	
1. INTRODUCTION	1
2. LITERATURE REVIEW	8
2.1 Cholera disease	8
2.1.1 <i>Vibrio cholerae</i> species	8
2.1.2 Disease pathogenesis and clinical features	9
2.1.3 Epidemiology of disease	13
2.1.4 Treatment for disease	17
2.1.5 Animal models of cholera disease	18
2.2 Vaccines	21
2.2.1 Antigenic peptides or proteins of <i>Vibrio sp.</i> bacteria	21
2.2.2 Cholera vaccines	23
2.2.3 DNA vaccines	26
2.2.3.1 DNA vaccine design	26
2.2.3.2 Routes of administration for DNA vaccination	28
2.2.3.3 Immune response to DNA vaccine	31
2.2.3.4 Adjuvants and booster immunizations	32
2.2.3.5 Advantages of DNA vaccination	34
2.2.3.6 Non-viral carriers for DNA vaccines	35
2.3 Alginate	36
2.3.1 Nature of alginates	36
2.3.2 Chemical properties of alginates	38
2.3.3 Formation of gels, beads and particles using alginates	40
2.3.4 Advantages of alginates	44
2.3.5 Industrial and/or pharmaceutical applications of alginates	45
2.4 Immune responses	47
2.4.1 Mucosal immunization	47
2.4.2 Mucosal immune system	48
2.4.3 Challenges of mucosal immunization	52

3. METHODOLOGY	53
3.1 Genomic DNA extraction form <i>Vibrio cholerae</i> bacterial isolates	53
3.2 Gene amplification through polymerase chain reaction (PCR)	55
3.3 Plasmid vector constructs	57
3.3.1 pVAX- <i>ctxB</i> vaccine construct	59
3.3.2 pVAX- <i>tcpA</i> vaccine construct	61
3.3.3 pVAX-GFP (green fluorescent protein) reporter gene construct	62
3.4 Mammalian cell transfection with eukaryotic expression vectors: pVAX-GFP, pVAX- <i>ctxB</i> and pVAX- <i>tcpA</i>	64
3.4.1 Cell transfection with Lipofectamine™ reagent	64
3.4.2 Cell transfection with polyethyleneimine (PEI) cationic polymer	66
3.5 <i>In vitro</i> protein expression mediated through pVAX-GFP as reporter gene plasmid vector	68
3.6 <i>In vitro</i> mRNA expression mediated through pVAX- <i>ctxB</i> and pVAX- <i>tcpA</i> plasmid constructs	69
3.7 Cell-free protein expression for cholera enterotoxin B subunit (CTB) and toxin coregulated pilin A (TcpA) proteins, mediated through pVAX- <i>ctxB</i> and pVAX- <i>tcpA</i> plasmid constructs	70
3.8 Immunofluorescence detection of <i>in vitro</i> CTB protein expression mediated through pVAX- <i>ctxB</i> plasmid constructs	73
3.9 Formation of alginate microspheres: Emulsification technique	75
3.10 Determination of microsphere diameter sizes and morphology	76
3.11 Encapsulation of pDNA into alginate microspheres	77
3.12 pDNA loading and encapsulation efficiency	78
3.13 Simulated gastrointestinal pH conditions and <i>in vitro</i> pDNA release from alginate microspheres	79
3.14 Functional assay for recovered pDNA	80
3.15 Oral pDNA delivery of loaded microspheres in mice	80
3.16 Sample processing for flow cytometric analysis	83
3.17 Mice vaccination with pVAX- <i>ctxB</i> DNA vaccine encapsulated within alginate microspheres	83
3.18 Secretory immunoglobulin A (sIgA) enzyme-linked immunsorbent assay in dosed mice	84
3.19 Cytokine measurements in serum samples among dosed mice	85
3.20 Rabbit vaccination with pVAX- <i>ctxB</i> or pVAX- <i>ctxB</i> and pVAX- <i>tcpA</i> combination DNA vaccine encapsulated within alginate microspheres	86
3.21 Measurement of secretory immunoglobulin A (sIgA) and serum IgA antibodies among dosed rabbits through enzyme-linked immunsorbent assay	88
3.22 Measurement of specific IgM- and IgG- anti-CTB and specific IgM- and IgG- anti-TcpA antibodies among dosed rabbits through enzyme-linked immunsorbent assay	88
3.23 Statistical analysis	89

4. RESULTS	90
4.1 <i>Vibrio cholerae</i> growth on TCBS agar	90
4.2 <i>Vibrio cholerae</i> genomic DNA on agarose gel	91
4.3 Polymerase chain reaction (PCR) result for <i>ctxB</i> and <i>tcpA</i> gene	92
4.4 Plasmid vector constructs	94
4.5 pVAX–GFP reporter gene plasmid construct: GFP expression among pVAX–GFP-transfected COS-7 cells	96
4.6 pVAX– <i>ctxB</i> and pVAX– <i>tcpA</i> vaccine constructs: mRNA expression among pDNA-transfected COS-7 cells	98
4.7 pVAX– <i>ctxB</i> and pVAX– <i>tcpA</i> vaccine constructs: Cell-free protein expression for CTB and TcpA proteins	99
4.8 pVAX– <i>ctxB</i> vaccine constructs: CTB protein expression detected through immunofluorescence staining	102
4.9 Microsphere characterization	104
4.10 pDNA loading and encapsulation efficiency (<i>EE%</i>)	109
4.11 Simulated gastrointestinal pH conditions and <i>in vitro</i> pDNA release from alginate microspheres	111
4.12 Oral pDNA delivery of loaded microspheres in mice	114
4.13 Post-vaccination serum and gut responses among mice	118
4.14 Post-vaccination serum and gut responses among rabbits	121
5. DISCUSSION	132
5.1 Cholera DNA vaccine constructs	132
5.2 Formation processes for alginate microspheres	135
5.3 General properties of alginate microspheres	135
5.4 Factors influencing alginate microsphere formation	137
5.5 Plasmid DNA entrapment and release from within alginate microspheres	143
5.6 Use of alginate microspheres as oral delivery system	143
5.7 Immunization process and immune response to DNA	147
5.7.1 Host responses to mucosal immunization	147
5.7.2 Evaluation of the pDNA dose for immunization	148
5.7.3 Non-specific responses to DNA vaccine	149
5.7.4 Immunoglobulin response during immunization process	150
5.7.5 Cellular-mediated response during immunization process	153
5.7.6 Challenges in the assessment of vaccine efficiency and achievement of immune status	153
6. CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCH	156
REFERENCES	158
APPENDICES	180
BIODATA OF STUDENT	228
LIST OF PUBLICATIONS	229